Camilla Languille Camilla Languille was elected to the board of directors in September 2024. Ms. Languille is currently Co-Chief Executive Officer of Mubadala Investment Company’s Private Equity platform, which executes global direct investments in buyout and growth equity and actively manages a portfolio targeting growth-oriented companies across a range of sectors, including Healthcare, Consumer, Technology, Financial Services, Industrial & Business Services, and Energy & Sustainability. Ms. Languille is Co-Chair of Mubadala’s Direct Investments Platform Investment Committee and a member of Mubadala’s Group Investment Committee. Ms. Languille has been with Mubadala Direct Investments since 2013 and has been instrumental in leading the buildout of its Healthcare portfolio and investments team. As the Head of Healthcare, Ms. Languille was responsible for executing investments in PCI Pharma, Envirotainer, Evotec, and Norstella, amongst others, and for building a 25-person global investments team across Abu Dhabi, New York, London, and Beijing. Prior to launching Mubadala’s Healthcare business, Ms. Languille was responsible for managing its semiconductor portfolio, overseeing its investment in GF and leading the monetization of Mubadala’s shareholding in Advanced Micro Devices. She began her career in Mubadala working with the Utilities and Mining portfolios. Prior to joining Mubadala, Ms. Languille previously worked in M&A for Daiwa Capital and Société Générale based in Paris, as well as in investments for Virgin Group in London, where she managed the Special Situations portfolio and helped to launch Virgin Healthcare. She began her career in Healthcare M&A for JPMorgan in New York and London. Ms. Languille currently serves on the boards of Evotec SE and PCI Pharma Services. Ms. Languille holds a Bachelor’s degree in Economics & Political Science from Columbia University. • People & Compensation Committee Member • Strategy & Technology Committee Member
